Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline

Eur J Heart Fail. 2019 Mar;21(3):386-388. doi: 10.1002/ejhf.1419. Epub 2019 Feb 14.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benzhydryl Compounds / pharmacology*
  • Cardiotonic Agents / pharmacology
  • Comorbidity
  • Diabetes Mellitus, Type 2* / drug therapy
  • Diabetes Mellitus, Type 2* / epidemiology
  • Glucosides / pharmacology*
  • Heart Failure* / epidemiology
  • Heart Failure* / physiopathology
  • Heart Failure* / prevention & control
  • Hemodynamics / drug effects
  • Humans
  • Hypoglycemic Agents / pharmacology
  • Randomized Controlled Trials as Topic
  • Sodium-Glucose Transporter 2 Inhibitors* / pharmacology
  • Treatment Outcome

Substances

  • Benzhydryl Compounds
  • Cardiotonic Agents
  • Glucosides
  • Hypoglycemic Agents
  • Sodium-Glucose Transporter 2 Inhibitors
  • empagliflozin

Associated data

  • ClinicalTrials.gov/NCT01131676